Intrua Financial LLC Has $867,000 Stock Position in Bristol Myers Squibb Company $BMY

Intrua Financial LLC cut its stake in Bristol Myers Squibb Company (NYSE:BMY) by 17.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,738 shares of the biopharmaceutical company’s stock after selling 3,878 shares during the period. Intrua Financial LLC’s holdings in Bristol Myers Squibb were worth $867,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Wellington Management Group LLP boosted its stake in shares of Bristol Myers Squibb by 297.0% in the 1st quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company’s stock valued at $1,447,198,000 after purchasing an additional 17,750,938 shares in the last quarter. GQG Partners LLC lifted its holdings in Bristol Myers Squibb by 22,647.6% during the 1st quarter. GQG Partners LLC now owns 12,023,454 shares of the biopharmaceutical company’s stock valued at $733,310,000 after purchasing an additional 11,970,598 shares during the last quarter. Nuveen LLC acquired a new position in Bristol Myers Squibb in the first quarter valued at about $624,369,000. Kingstone Capital Partners Texas LLC bought a new stake in Bristol Myers Squibb during the second quarter worth about $98,898,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Bristol Myers Squibb by 17.7% during the first quarter. Goldman Sachs Group Inc. now owns 14,051,319 shares of the biopharmaceutical company’s stock worth $856,990,000 after buying an additional 2,117,249 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, October 13th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Scotiabank initiated coverage on shares of Bristol Myers Squibb in a research note on Thursday. They issued a “sector perform” rating and a $45.00 target price for the company. Finally, Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target on the stock. in a research note on Tuesday, August 5th. Four investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus target price of $54.58.

Insiders Place Their Bets

In other news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This trade represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Trading Down 4.0%

NYSE BMY opened at $46.67 on Friday. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33. The stock has a 50-day simple moving average of $45.34 and a 200 day simple moving average of $46.70. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The company has a market capitalization of $95.00 billion, a PE ratio of 18.82, a P/E/G ratio of 2.23 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. The firm had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company’s revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd were paid a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.3%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is presently 83.78%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.